Search research articles
Contact Us
Filters
Showing results (101-110 of 135) with videos related to
Page
of 14
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
American Journal of Hematology
|
January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
Matthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
Blood Advances
|
February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma
William A Wood, Shaji K Kumar, Emily Semmel, et al.
Blood Advances
|
March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing
Carlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances
|
May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Benjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2021
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Francesco Maura, Benjamin Diamond, Kylee H Maclachlan, et al.
Nature Communications
|
March 26, 2021
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
Bénedith Oben, Guy Froyen, Kylee H Maclachlan, et al.
NPJ Breast Cancer
|
September 23, 2020
Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast
Clara Bodelon, Hannah Oh, Andriy Derkach, et al.
American Journal of Hematology
|
March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasone
Neha Korde, Donna Mastey, Elizabet Tavitian, et al.
Nature Medicine
|
August 15, 2024
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Justin Jee, A Rose Brannon, Rohan Singh, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 135) with videos related to
Sort By:
Page
of 14
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
American Journal of Hematology
|
January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
Matthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
Blood Advances
|
February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma
William A Wood, Shaji K Kumar, Emily Semmel, et al.
Blood Advances
|
March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing
Carlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances
|
May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Benjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2021
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Francesco Maura, Benjamin Diamond, Kylee H Maclachlan, et al.
Nature Communications
|
March 26, 2021
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
Bénedith Oben, Guy Froyen, Kylee H Maclachlan, et al.
NPJ Breast Cancer
|
September 23, 2020
Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast
Clara Bodelon, Hannah Oh, Andriy Derkach, et al.
American Journal of Hematology
|
March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasone
Neha Korde, Donna Mastey, Elizabet Tavitian, et al.
Nature Medicine
|
August 15, 2024
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Justin Jee, A Rose Brannon, Rohan Singh, et al.
Page
of 14